Strategies like bilateral oophorectomy, LH-RH antagonists, and antiestrogens such as tamoxifen have demonstrated success in breast cancer, yielding regression rates of 17 to 35 percent in sensitive tumors. Here, GNRH1 is linked to breast carcinoma.